Regimen Options
Last Updated: 10/01/2026 See Details
| Evolent Pathways | Febrile Neutropenic Risk | Emetogenic Risk | References | ||
|---|---|---|---|---|---|
| NON-METASTATIC | |||||
Definitive Chemoradiation |
mitomycin and 5FU (fluorouracil) |
Low | Low |
|
|
mitomycin and capecitabine |
Low | Low | |||
| ADVANCED/METASTATIC | |||||
Initial Therapy |
carboplatin and paclitaxel |
Low | High |
|
|
carboplatin, paclitaxel and retifanlimab |
Low | High |
|
||
Subsequent Therapy |
Best Supportive Care or Clinical Trial |
Not Applicable | Not applicable |
|
|
NON-METASTATIC
Definitive Chemoradiation
Evolent Pathways
mitomycin and 5FU (fluorouracil)
Febrile Neutropenic Risk
low
Emetogenic Risk
low
References
Evolent Pathways
mitomycin and capecitabine
Febrile Neutropenic Risk
low
Emetogenic Risk
low
ADVANCED/METASTATIC
Initial Therapy
Evolent Pathways
carboplatin and paclitaxel
Febrile Neutropenic Risk
low
Emetogenic Risk
high
References
Evolent Pathways
carboplatin, paclitaxel and retifanlimab
Febrile Neutropenic Risk
low
Emetogenic Risk
high
References
Subsequent Therapy
Evolent Pathways
Best Supportive Care or Clinical Trial
Febrile Neutropenic Risk
na
Emetogenic Risk
na
References